Anavex Life Sciences Corp. (AVXL) 10-Year Financial Performance & Capital Metrics

AVXL • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

AboutAnavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Show more

Revenue $0
EBITDA $0 +100.0%
Net Income $0 +100.0%
EPS (Diluted) -0.54 -3.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 5 (bottom 5%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-15.99%

EPS CAGR

10Y-

5Y-

3Y-

TTM-14%

ROCE

10Y Avg-87.09%

5Y Avg-40.35%

3Y Avg-39.78%

Latest-

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Sales/Revenue+	0	0	0	-685K	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	1%	-	-	-	-	-
Cost of Goods Sold+	1.25K	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-1.25K	0	0	0	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	1%	-	-	-	-	-	-	-	-
Operating Expenses+	14.88M	15.54M	19.18M	29.11M	30.94M	41.95M	50.99M	55.76M	52.88M	51.41M
OpEx % of Revenue	-	-	-	-42.49%	-	-	-	-	-	-
Selling, General & Admin	8.33M	5.01M	6.14M	6.85M	5.86M	9.15M	13.07M	12.04M	11.04M	13.82M
SG&A % of Revenue	-	-	-	-10%	-	-	-	-	-	-
Research & Development	7.25M	10.67M	13.34M	22.26M	25.23M	32.98M	37.92M	43.72M	41.84M	37.59M
R&D % of Revenue	-	-	-	-32.5%	-	-	-	-	-	-
Other Operating Expenses	151.4K	0	0	0	-151K	-186K	0	0	0	0
Operating Income+	-15.59M	-15.54M	-19.18M	-28.75M	-31.09M	-41.92M	-50.99M	-55.76M	-52.88M	0
Operating Margin %	-	-	-	41.97%	-	-	-	-	-	-
Operating Income Growth %	-1.19%	0%	-0.23%	-0.5%	-0.08%	-0.35%	-0.22%	-0.09%	0.05%	1%
EBITDA+	-15.59M	-15.54M	-1.68M	-2.11M	-30.63M	-4.47M	-54.31M	-58.47M	-2.29M	0
EBITDA Margin %	-	-	-	3.08%	-	-	-	-	-	-
EBITDA Growth %	-1.19%	0%	0.89%	-0.26%	-13.51%	0.85%	-11.16%	-0.08%	0.96%	1%
D&A (Non-Cash Add-back)	1.25K	1.25K	17.5M	26.64M	0	37.45M	-3.32M	-2.72M	50.59M	0
EBIT	-15.02M	-15.42M	-18.98M	-28.53M	-30.63M	-42.19M	-50.94M	-53.04M	-45.29M	0
Net Interest Income+	-11.31M	0	224.15K	56.15K	179.97K	26.26K	0	5.55M	7.32M	0
Interest Income	11.32K	88.1K	255.09K	207.28K	179.97K	26.26K	946.99K	6.52M	7.32M	0
Interest Expense	11.32M	0	30.94K	151.13K	0	0	946.99K	964K	0	0
Other Income/Expense	881.96K	2.28M	2.1M	3.08M	4.83M	4.28M	3.37M	8.26M	9.88M	0
Pretax Income+	-14.71M	-13.4M	-17.18M	-26.21M	-26.26M	-37.64M	-47.62M	-47.5M	-43M	0
Pretax Margin %	-	-	-	38.27%	-	-	-	-	-	-
Income Tax+	29.61K	59.61K	72.75K	82.18K	22.66K	267.56K	358.49K	7K	0	0
Effective Tax Rate %	1%	1%	1.02%	1%	1%	1.01%	1.01%	1%	1%	-
Net Income+	-14.74M	-13.46M	-17.45M	-26.3M	-26.28M	-37.91M	-47.98M	-47.51M	-43M	0
Net Margin %	-	-	-	38.39%	-	-	-	-	-	-
Net Income Growth %	-0.22%	0.09%	-0.3%	-0.51%	0%	-0.44%	-0.27%	0.01%	0.09%	1%
Net Income (Continuing)	-14.74M	-13.46M	-17.25M	-26.3M	-26.28M	-37.91M	-47.98M	-47.51M	-43M	0
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.42	-0.33	-0.39	-0.54	-0.45	-0.54	-0.62	-0.60	-0.52	-0.54
EPS Growth %	0.35%	0.21%	-0.18%	-0.38%	0.17%	-0.2%	-0.15%	0.03%	0.13%	-0.04%
EPS (Basic)	-0.42	-0.33	-0.39	-0.54	-0.45	-0.54	-0.62	-0.60	-0.52	-0.54
Diluted Shares Outstanding	35.15M	40.84M	44.66M	48.91M	58.2M	69.8M	76.91M	79.79M	83.47M	85.29M
Basic Shares Outstanding	35.15M	40.84M	44.66M	48.91M	58.2M	69.8M	76.91M	79.79M	83.47M	85.29M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Total Current Assets+	9.45M	27.79M	24.32M	25.33M	34.54M	161.62M	152.7M	154.39M	135.57M	103.81M
Cash & Short-Term Investments	9.19M	27.44M	22.93M	22.19M	29.25M	152.11M	149.16M	151.02M	132.19M	102.58M
Cash Only	9.19M	27.44M	22.93M	22.19M	29.25M	152.11M	149.16M	151.02M	132.19M	102.58M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	79.35K	9.75K	1.87M	2.64M	4.85M	9.14M	3.19M	2.71M	2.45M	809K
Days Sales Outstanding	-	-	-	-1.41K	-	-	-	-	-	-
Inventory	0	0	0	-2.64M	0	16.36K	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	2.64M	0	-16.36K	162	653K	931K	429K
Total Non-Current Assets+	52.4K	52.4K	52.4K	0	5.29M	16.36K	3.55B	3.36M	0	0
Property, Plant & Equipment	0	0	0	0	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	52.4K	52.4K	52.4K	0	5.29M	16.36K	3.55B	3.36M	0	0
Total Assets+	9.5M	27.84M	24.38M	25.33M	34.54M	161.62M	152.7M	154.39M	135.57M	103.81M
Asset Turnover	-	-	-	-0.03x	-	-	-	-	-	-
Asset Growth %	-0.39%	1.93%	-0.12%	0.04%	0.36%	3.68%	-0.06%	0.01%	-0.12%	-0.23%
Total Current Liabilities+	3.19M	3.58M	3.88M	5.04M	7.31M	10.8M	10.21M	12.53M	15.3M	8.95M
Accounts Payable	3.06M	3.58M	2.96M	3.52M	3.99M	4.74M	3.82M	4.32M	9.63M	4.25M
Days Payables Outstanding	892.31K	-	-	-	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	70.53K	0	0	0	0	443.83K	443.83K	0	842K	805K
Other Current Liabilities	70.53K	0	0	0	0	0	-47	6.85M	1.53M	1.56M
Current Ratio	2.96x	7.75x	6.26x	5.03x	4.73x	14.97x	14.95x	12.32x	8.86x	11.60x
Quick Ratio	2.96x	7.75x	6.26x	5.55x	4.73x	14.97x	14.95x	12.32x	8.86x	11.60x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	0	0	0	0	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	3.19M	3.58M	3.88M	5.04M	7.31M	10.8M	10.21M	12.53M	15.3M	8.95M
Total Debt+	0	0	0	0	0	0	0	0	0	0
Net Debt	-9.19M	-27.44M	-22.93M	-22.19M	-29.25M	-152.11M	-149.16M	-151.02M	-132.19M	-102.58M
Debt / Equity	-	-	-	-	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-1.38x	-	-620.01x	-190.24x	-	-	-53.84x	-57.84x	-	-
Total Equity+	6.31M	24.25M	20.49M	20.29M	27.24M	150.82M	142.49M	141.85M	120.26M	94.87M
Equity Growth %	-0.51%	2.84%	-0.16%	-0.01%	0.34%	4.54%	-0.06%	-0%	-0.15%	-0.21%
Book Value per Share	0.18	0.59	0.46	0.41	0.47	2.16	1.85	1.78	1.44	1.11
Total Shareholders' Equity	6.31M	24.25M	20.49M	20.29M	27.24M	150.82M	142.49M	141.85M	120.26M	94.87M
Common Stock	36.17K	43.33K	45.94K	52.65K	62.05K	75.92K	77.94K	82K	85K	87K
Retained Earnings	-78.02M	-91.48M	-108.93M	-133.4M	-159.68M	-197.59M	-245.56M	-293.07M	-336.07M	-382.45M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Cash from Operations+	-9.24M	-9.02M	-12.58M	-18.53M	-21.29M	-30.38M	-24.24M	-27.79M	-30.81M	-39.04M
Operating CF Margin %	-	-	-	27.05%	-	-	-	-	-	-
Operating CF Growth %	-1.19%	0.02%	-0.4%	-0.47%	-0.15%	-0.43%	0.2%	-0.15%	-0.11%	-0.27%
Net Income	-14.74M	-13.46M	-17.45M	-26.29M	-26.28M	-37.91M	-47.98M	-47.51M	-43M	-46.38M
Depreciation & Amortization	1.25K	0	0	0	0	0	0	0	0	0
Stock-Based Compensation	5.06M	4.14M	5.52M	6.43M	4.88M	8.23M	18.38M	16.37M	9.44M	11.55M
Deferred Taxes	-58.14K	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	-145.57K	-75.2K	5.61M	35.38K	0	403	242	845K	0	-4.22M
Working Capital Changes	640.07K	382.81K	-646K	1.3M	116.52K	-706.44K	5.36M	2.5M	2.75M	0
Change in Receivables	-2.51K	54.44K	-231.1K	-772.39K	-2.21M	-4.29M	5.94M	484K	260K	0
Change in Inventory	0	0	0	772.39K	2.21M	4.29M	-5.94M	0	0	0
Change in Payables	-151.4M	554.71K	38.23K	683.8K	465.72K	750.73K	-915K	497K	5.3M	-5.38M
Cash from Investing+	0	0	0	0	0	0	0	0	0	0
Capital Expenditures	0	0	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	3.13M	27.27M	8.07M	17.78M	28.35M	153.24M	21.29M	29.65M	11.97M	9.43M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	3.13M	0	-101.13K	-50K	-403.76K	23.4K	0	1.78M	691K	9.43M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.24M	-9.02M	-12.58M	-18.53M	-21.29M	-30.38M	-24.24M	-27.79M	-30.81M	-39.04M
FCF Margin %	-	-	-	27.05%	-	-	-	-	-	-
FCF Growth %	-1.19%	0.02%	-0.4%	-0.47%	-0.15%	-0.43%	0.2%	-0.15%	-0.11%	-0.27%
FCF per Share	-0.26	-0.22	-0.28	-0.38	-0.37	-0.44	-0.32	-0.35	-0.37	-0.46
FCF Conversion (FCF/Net Income)	0.63x	0.67x	0.72x	0.70x	0.81x	0.80x	0.51x	0.58x	0.72x	-
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	22.66K	140K	327K	136K	300K	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-154.18%	-88.08%	-78.01%	-128.96%	-110.59%	-42.58%	-32.71%	-33.41%	-32.81%	-
Net Margin	-	-	-	3838.69%	-	-	-	-	-	-
Interest Coverage	-1.38x	-	-620.01x	-190.24x	-	-	-53.84x	-57.84x	-	-
FCF Conversion	0.63x	0.67x	0.72x	0.70x	0.81x	0.80x	0.51x	0.58x	0.72x	-
Revenue Growth	-	-	-	-	100%	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Anavex Life Sciences Corp. (AVXL) grew revenue by 0.0% over the past year. Growth has been modest.

Anavex Life Sciences Corp. (AVXL) reported a net loss of $48.2M for fiscal year 2025.

Dividend & Returns

Anavex Life Sciences Corp. (AVXL) had negative free cash flow of $37.1M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

Anavex Life Sciences Corp. (AVXL) 10-Year Financial Performance & Capital Metrics

AVXL • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

Revenue $0
EBITDA $0 +100.0%
Net Income $0 +100.0%
EPS (Diluted) -0.54 -3.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 5 (bottom 5%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-15.99%

EPS CAGR

10Y-

5Y-

3Y-

TTM-14%

ROCE

10Y Avg-87.09%

5Y Avg-40.35%

3Y Avg-39.78%

Latest-

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Sales/Revenue+	0	0	0	-685K	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	1%	-	-	-	-	-
Cost of Goods Sold+	1.25K	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-1.25K	0	0	0	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	1%	-	-	-	-	-	-	-	-
Operating Expenses+	14.88M	15.54M	19.18M	29.11M	30.94M	41.95M	50.99M	55.76M	52.88M	51.41M
OpEx % of Revenue	-	-	-	-42.49%	-	-	-	-	-	-
Selling, General & Admin	8.33M	5.01M	6.14M	6.85M	5.86M	9.15M	13.07M	12.04M	11.04M	13.82M
SG&A % of Revenue	-	-	-	-10%	-	-	-	-	-	-
Research & Development	7.25M	10.67M	13.34M	22.26M	25.23M	32.98M	37.92M	43.72M	41.84M	37.59M
R&D % of Revenue	-	-	-	-32.5%	-	-	-	-	-	-
Other Operating Expenses	151.4K	0	0	0	-151K	-186K	0	0	0	0
Operating Income+	-15.59M	-15.54M	-19.18M	-28.75M	-31.09M	-41.92M	-50.99M	-55.76M	-52.88M	0
Operating Margin %	-	-	-	41.97%	-	-	-	-	-	-
Operating Income Growth %	-1.19%	0%	-0.23%	-0.5%	-0.08%	-0.35%	-0.22%	-0.09%	0.05%	1%
EBITDA+	-15.59M	-15.54M	-1.68M	-2.11M	-30.63M	-4.47M	-54.31M	-58.47M	-2.29M	0
EBITDA Margin %	-	-	-	3.08%	-	-	-	-	-	-
EBITDA Growth %	-1.19%	0%	0.89%	-0.26%	-13.51%	0.85%	-11.16%	-0.08%	0.96%	1%
D&A (Non-Cash Add-back)	1.25K	1.25K	17.5M	26.64M	0	37.45M	-3.32M	-2.72M	50.59M	0
EBIT	-15.02M	-15.42M	-18.98M	-28.53M	-30.63M	-42.19M	-50.94M	-53.04M	-45.29M	0
Net Interest Income+	-11.31M	0	224.15K	56.15K	179.97K	26.26K	0	5.55M	7.32M	0
Interest Income	11.32K	88.1K	255.09K	207.28K	179.97K	26.26K	946.99K	6.52M	7.32M	0
Interest Expense	11.32M	0	30.94K	151.13K	0	0	946.99K	964K	0	0
Other Income/Expense	881.96K	2.28M	2.1M	3.08M	4.83M	4.28M	3.37M	8.26M	9.88M	0
Pretax Income+	-14.71M	-13.4M	-17.18M	-26.21M	-26.26M	-37.64M	-47.62M	-47.5M	-43M	0
Pretax Margin %	-	-	-	38.27%	-	-	-	-	-	-
Income Tax+	29.61K	59.61K	72.75K	82.18K	22.66K	267.56K	358.49K	7K	0	0
Effective Tax Rate %	1%	1%	1.02%	1%	1%	1.01%	1.01%	1%	1%	-
Net Income+	-14.74M	-13.46M	-17.45M	-26.3M	-26.28M	-37.91M	-47.98M	-47.51M	-43M	0
Net Margin %	-	-	-	38.39%	-	-	-	-	-	-
Net Income Growth %	-0.22%	0.09%	-0.3%	-0.51%	0%	-0.44%	-0.27%	0.01%	0.09%	1%
Net Income (Continuing)	-14.74M	-13.46M	-17.25M	-26.3M	-26.28M	-37.91M	-47.98M	-47.51M	-43M	0
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.42	-0.33	-0.39	-0.54	-0.45	-0.54	-0.62	-0.60	-0.52	-0.54
EPS Growth %	0.35%	0.21%	-0.18%	-0.38%	0.17%	-0.2%	-0.15%	0.03%	0.13%	-0.04%
EPS (Basic)	-0.42	-0.33	-0.39	-0.54	-0.45	-0.54	-0.62	-0.60	-0.52	-0.54
Diluted Shares Outstanding	35.15M	40.84M	44.66M	48.91M	58.2M	69.8M	76.91M	79.79M	83.47M	85.29M
Basic Shares Outstanding	35.15M	40.84M	44.66M	48.91M	58.2M	69.8M	76.91M	79.79M	83.47M	85.29M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Total Current Assets+	9.45M	27.79M	24.32M	25.33M	34.54M	161.62M	152.7M	154.39M	135.57M	103.81M
Cash & Short-Term Investments	9.19M	27.44M	22.93M	22.19M	29.25M	152.11M	149.16M	151.02M	132.19M	102.58M
Cash Only	9.19M	27.44M	22.93M	22.19M	29.25M	152.11M	149.16M	151.02M	132.19M	102.58M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	79.35K	9.75K	1.87M	2.64M	4.85M	9.14M	3.19M	2.71M	2.45M	809K
Days Sales Outstanding	-	-	-	-1.41K	-	-	-	-	-	-
Inventory	0	0	0	-2.64M	0	16.36K	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	2.64M	0	-16.36K	162	653K	931K	429K
Total Non-Current Assets+	52.4K	52.4K	52.4K	0	5.29M	16.36K	3.55B	3.36M	0	0
Property, Plant & Equipment	0	0	0	0	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	52.4K	52.4K	52.4K	0	5.29M	16.36K	3.55B	3.36M	0	0
Total Assets+	9.5M	27.84M	24.38M	25.33M	34.54M	161.62M	152.7M	154.39M	135.57M	103.81M
Asset Turnover	-	-	-	-0.03x	-	-	-	-	-	-
Asset Growth %	-0.39%	1.93%	-0.12%	0.04%	0.36%	3.68%	-0.06%	0.01%	-0.12%	-0.23%
Total Current Liabilities+	3.19M	3.58M	3.88M	5.04M	7.31M	10.8M	10.21M	12.53M	15.3M	8.95M
Accounts Payable	3.06M	3.58M	2.96M	3.52M	3.99M	4.74M	3.82M	4.32M	9.63M	4.25M
Days Payables Outstanding	892.31K	-	-	-	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	70.53K	0	0	0	0	443.83K	443.83K	0	842K	805K
Other Current Liabilities	70.53K	0	0	0	0	0	-47	6.85M	1.53M	1.56M
Current Ratio	2.96x	7.75x	6.26x	5.03x	4.73x	14.97x	14.95x	12.32x	8.86x	11.60x
Quick Ratio	2.96x	7.75x	6.26x	5.55x	4.73x	14.97x	14.95x	12.32x	8.86x	11.60x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	0	0	0	0	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	3.19M	3.58M	3.88M	5.04M	7.31M	10.8M	10.21M	12.53M	15.3M	8.95M
Total Debt+	0	0	0	0	0	0	0	0	0	0
Net Debt	-9.19M	-27.44M	-22.93M	-22.19M	-29.25M	-152.11M	-149.16M	-151.02M	-132.19M	-102.58M
Debt / Equity	-	-	-	-	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-1.38x	-	-620.01x	-190.24x	-	-	-53.84x	-57.84x	-	-
Total Equity+	6.31M	24.25M	20.49M	20.29M	27.24M	150.82M	142.49M	141.85M	120.26M	94.87M
Equity Growth %	-0.51%	2.84%	-0.16%	-0.01%	0.34%	4.54%	-0.06%	-0%	-0.15%	-0.21%
Book Value per Share	0.18	0.59	0.46	0.41	0.47	2.16	1.85	1.78	1.44	1.11
Total Shareholders' Equity	6.31M	24.25M	20.49M	20.29M	27.24M	150.82M	142.49M	141.85M	120.26M	94.87M
Common Stock	36.17K	43.33K	45.94K	52.65K	62.05K	75.92K	77.94K	82K	85K	87K
Retained Earnings	-78.02M	-91.48M	-108.93M	-133.4M	-159.68M	-197.59M	-245.56M	-293.07M	-336.07M	-382.45M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Cash from Operations+	-9.24M	-9.02M	-12.58M	-18.53M	-21.29M	-30.38M	-24.24M	-27.79M	-30.81M	-39.04M
Operating CF Margin %	-	-	-	27.05%	-	-	-	-	-	-
Operating CF Growth %	-1.19%	0.02%	-0.4%	-0.47%	-0.15%	-0.43%	0.2%	-0.15%	-0.11%	-0.27%
Net Income	-14.74M	-13.46M	-17.45M	-26.29M	-26.28M	-37.91M	-47.98M	-47.51M	-43M	-46.38M
Depreciation & Amortization	1.25K	0	0	0	0	0	0	0	0	0
Stock-Based Compensation	5.06M	4.14M	5.52M	6.43M	4.88M	8.23M	18.38M	16.37M	9.44M	11.55M
Deferred Taxes	-58.14K	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	-145.57K	-75.2K	5.61M	35.38K	0	403	242	845K	0	-4.22M
Working Capital Changes	640.07K	382.81K	-646K	1.3M	116.52K	-706.44K	5.36M	2.5M	2.75M	0
Change in Receivables	-2.51K	54.44K	-231.1K	-772.39K	-2.21M	-4.29M	5.94M	484K	260K	0
Change in Inventory	0	0	0	772.39K	2.21M	4.29M	-5.94M	0	0	0
Change in Payables	-151.4M	554.71K	38.23K	683.8K	465.72K	750.73K	-915K	497K	5.3M	-5.38M
Cash from Investing+	0	0	0	0	0	0	0	0	0	0
Capital Expenditures	0	0	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	3.13M	27.27M	8.07M	17.78M	28.35M	153.24M	21.29M	29.65M	11.97M	9.43M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	3.13M	0	-101.13K	-50K	-403.76K	23.4K	0	1.78M	691K	9.43M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.24M	-9.02M	-12.58M	-18.53M	-21.29M	-30.38M	-24.24M	-27.79M	-30.81M	-39.04M
FCF Margin %	-	-	-	27.05%	-	-	-	-	-	-
FCF Growth %	-1.19%	0.02%	-0.4%	-0.47%	-0.15%	-0.43%	0.2%	-0.15%	-0.11%	-0.27%
FCF per Share	-0.26	-0.22	-0.28	-0.38	-0.37	-0.44	-0.32	-0.35	-0.37	-0.46
FCF Conversion (FCF/Net Income)	0.63x	0.67x	0.72x	0.70x	0.81x	0.80x	0.51x	0.58x	0.72x	-
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	22.66K	140K	327K	136K	300K	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-154.18%	-88.08%	-78.01%	-128.96%	-110.59%	-42.58%	-32.71%	-33.41%	-32.81%	-
Net Margin	-	-	-	3838.69%	-	-	-	-	-	-
Interest Coverage	-1.38x	-	-620.01x	-190.24x	-	-	-53.84x	-57.84x	-	-
FCF Conversion	0.63x	0.67x	0.72x	0.70x	0.81x	0.80x	0.51x	0.58x	0.72x	-
Revenue Growth	-	-	-	-	100%	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Anavex Life Sciences Corp. (AVXL) grew revenue by 0.0% over the past year. Growth has been modest.

Anavex Life Sciences Corp. (AVXL) reported a net loss of $48.2M for fiscal year 2025.

Dividend & Returns

Anavex Life Sciences Corp. (AVXL) had negative free cash flow of $37.1M in fiscal year 2025, likely due to heavy capital investments.